Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Human papillomavirus vaccine recombinant quadrivalent - Merck

Drug Profile

Human papillomavirus vaccine recombinant quadrivalent - Merck

Alternative Names: Gardasil; Human papillomavirus (types 6, 11, 16, 18) L1 virus-like particle vaccine - Merck; Human papillomavirus (types 6, 11, 16, 18) L1 VLP vaccine - Merck; Human papillomavirus quadrivalent (types 6, 11, 16, 18) recombinant vaccine - Merck; q HPV; Quadrivalent human papillomavirus vaccine - Merck; Silgard; V 501

Latest Information Update: 23 Jan 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator CSL; The University of Queensland
  • Developer Banyu; Chongqing Zhifei Biological Products; CSL; Merck & Co; Merck Sharp & Dohme; National Cancer Institute (USA); The EMMES Corporation; University of Arkansas System; University of California at San Francisco
  • Class Cancer vaccines; Papillomavirus vaccines; Synthetic vaccines; Virus-like particle vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Anal cancer; Anal intraepithelial neoplasia; Cervical cancer; Gynaecological cancer; Human papillomavirus infections
  • Phase III Condylomata acuminata; Penile cancer

Most Recent Events

  • 31 Aug 2018 Phase-III clinical trials in Human papillomavirus infections (Prevention, In children, In adolescents, In adults) in China (IM) (NCT03493542)
  • 08 Aug 2018 Merck Sharp & Dohme completes a phase III trial for Human papillomavirus infections (Prevention, In children, In adolescents, In volunteers) in Japan (IM) (NCT02576054)
  • 12 Apr 2018 Merck & Co plans a phase III trial for prevention of HPV Types 16- and 18-related cervical cancer in situ in unknown location in July 2018 (NCT03493542)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top